Recombinant SARS-Cov-2 Variant Bank
Several new variants of SARS-CoV-2 virus have emerged in recent months. The alpha variant B.1.1.7, the beta variant B.1.351, the gamma variant P.1, and the most recent delta variant B.1.617 are of particular concern because of their high prevalence. A subset of the mutations identified in the RBD domain of the spike protein occurs in more than one strain. These convergent mutations are of high interest because they may be the cause of the increased transmissibility. Sino Biological has launched RBD and spike proteins of these variants, along with a new panel of corresponding neutralizing antibodies for variant neutralization and characterization.
The mutations in these strains also occur in the nucleocapsid protein, which is commonly used as the biomarker in rapid antigen tests. It’s critical to assess whether the current commercial antigen tests can detect the mutated N proteins with the same sensitivity and specificity as their WT counterpart.
Sino Biological has developed a panel of recombinant RBD/Spike and nucleocapsid protein variants which can be used to evaluate the efficacy of the antibodies and vaccination.
This content was supplied by Sino Biological.